RGEN
RGEN
NASDAQ · Life Sciences Tools & Services

Repligen Corp

$116.30
-0.05 (-0.04%)
Financial Highlights (FY 2026)
Revenue
737.26M
Net Income
48.83M
Gross Margin
52.6%
Profit Margin
6.6%
Rev Growth
-2.7%
D/E Ratio
0.26
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 52.6% 52.6% 33.3% 33.3%
Operating Margin 7.5% 6.7% 6.8% 6.5%
Profit Margin 6.6% 6.3% 7.1% 6.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 737.26M 757.72M 4.59B 4.00B
Gross Profit 388.17M 398.94M 1.53B 1.33B
Operating Income 55.07M 50.94M 311.12M 261.18M
Net Income 48.83M 45.16M 325.04M 256.90M
Gross Margin 52.6% 52.6% 33.3% 33.3%
Operating Margin 7.5% 6.7% 6.8% 6.5%
Profit Margin 6.6% 6.3% 7.1% 6.4%
Rev Growth -2.7% -2.7% +1.3% +8.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 658.39M 658.39M 1.77B 1.35B
Total Equity 2.56B 2.56B 3.56B 3.35B
D/E Ratio 0.26 0.26 0.50 0.40
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 136.54M 133.31M 499.02M 399.89M
Free Cash Flow 285.62M 226.18M